Search results for "HIP"

showing 10 items of 9327 documents

Dose-Related Effects of Amisulpride on Five Dimensions of Psychopathology in Patients With Acute Exacerbation of Schizophrenia

2002

The present analysis investigated symptom-specific dose-response relationships of the atypical antipsychotic amisulpride (AMI) in schizophrenic patients. The effects of different AMI doses on five different symptom dimensions of the Brief Psychiatric Rating Scale (BPRS) were analyzed. Results on global efficacy and safety parameters have been previously published. Four AMI doses (100 mg/day [AMI100], 400 mg/day [AMI400], 800 mg/day [AMI800], 1200 mg/day) were compared with 16 mg haloperidol (HAL16) in a multicenter, double-blind, randomized, parallel-group, 4-week trial. A total of 319 patients with acute exacerbation of schizophrenia (DSM-III-R) were included. AMI100 was compared with the …

AdultMalemedicine.medical_specialtyAdolescentExacerbationmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticInternal medicineBrief Psychiatric Rating ScalemedicineHaloperidolHumansPharmacology (medical)AmisulpridePsychiatryAntipsychoticPsychiatric Status Rating ScalesDose-Response Relationship DrugDopamine antagonistMiddle AgedPsychiatry and Mental healthTreatment OutcomeSchizophreniaHaloperidolAnxietyFemaleSchizophrenic PsychologyAmisulprideSulpiridemedicine.symptomPsychologyAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Short-term changes in median nerve neural tension after a suboccipital muscle inhibition technique in subjects with cervical whiplash: A randomised c…

2014

Abstract Objectives To assess the immediate effect of a suboccipital muscle inhibition (SMI) technique on: (a) neck pain, (b) elbow extension range of motion during the upper limb neurodynamic test of the median nerve (ULNT-1), and (c) grip strength in subjects with cervical whiplash; and determine the relationships between key variables. Design Randomised, single-blind, controlled clinical trial. Setting Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, Spain. Participants Forty subjects {mean age 34 years [standard deviation (SD) 3.6]} with Grade I or II cervical whiplash and a positive response to the ULNT-1 were recruited and distributed into two study groups: inter…

AdultMalemedicine.medical_specialtyAdolescentFisioteràpiaVisual analogue scaleColl MalaltiesElbowPhysical Therapy Sports Therapy and Rehabilitationlaw.inventionGrip strengthRandomized controlled triallawElbow JointmedicineWhiplashHumansSingle-Blind MethodRange of Motion ArticularPhysical Therapy ModalitiesWhiplash InjuriesPain MeasurementNeck painHand Strengthbusiness.industryMiddle Agedmedicine.diseaseMedian NerveColumna vertebralmedicine.anatomical_structureRehabilitacióPhysical therapyUpper limbFemalemedicine.symptomRange of motionbusiness
researchProduct

Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and h…

2000

Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter trial including 18 patients with refractory anemia with excess of blasts in transformation (RAEB-T), 86 patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndromes, and six patients with secondary AML after previous chemotherapy. Median age was 58 years (range: 18-76 years). Forty-nine patients (45%) achieved a complete remission (CR) after two induction cycles with idarubicin, ara-C, and etoposide, 52% of them aged/=60 years and 35% aged60 years (p=0.06). After two consolidation courses, patients were randomized to four cycles of either high-…

AdultMalemedicine.medical_specialtyAdolescentGastroenterologyInternal medicineMulticenter trialAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineIdarubicinProspective StudiesSurvival rateEtoposideAgedEtoposideDose-Response Relationship Drugbusiness.industryMyelodysplastic syndromesCytarabineHematologyGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival RateLeukemiaLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseCytarabineInterleukin-2FemaleImmunotherapyIdarubicinbusinessRefractory anemia with excess of blastsmedicine.drugAnnals of Hematology
researchProduct

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a …

2007

Abstract Background To compare the efficacy and safety of three different chemotherapy doublets in the treatment of advanced pancreatic cancer (PC). Patients and methods At total of 190 patients were randomly assigned to receive capecitabine 1000 mg/m2 twice daily on days 1–14 plus oxaliplatin 130 mg/m2 on day 1 (CapOx), capecitabine 825 mg/m2 twice daily on days 1–14 plus gemcitabine 1000 mg/m2 on days 1 and 8 (CapGem) or gemcitabine 1000 mg/m2 on days 1 and 8 plus oxaliplatin 130 mg/m2 on day 8 (mGemOx). Treatment cycles were repeated every three weeks. The primary end point was progression-free survival (PFS) rate at 3 months; secondary end points included objective response rate, carboh…

AdultMalemedicine.medical_specialtyAdolescentMaximum Tolerated DoseOrganoplatinum CompoundsPhases of clinical researchKaplan-Meier EstimateDeoxycytidineRisk AssessmentGastroenterologyDisease-Free SurvivalDrug Administration ScheduleCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSingle-Blind MethodProgression-free survivalInfusions IntravenousCapecitabineAgedNeoplasm StagingProbabilityDose-Response Relationship Drugbusiness.industryCAPOX RegimenHematologyMiddle AgedImmunohistochemistrySurvival AnalysisGemcitabineGemcitabineOxaliplatinSurgeryOxaliplatinPancreatic NeoplasmsRegimenTreatment OutcomeOncologyTolerabilityFemaleFluorouracilbusinessFollow-Up Studiesmedicine.drugAnnals of Oncology
researchProduct

Consensus meeting: monosodium glutamate – an update

2006

Update of the Hohenheim consensus on monosodium glutamate from 1997: Summary and evaluation of recent knowledge with respect to physiology and safety of monosodium glutamate.Experts from a range of relevant disciplines received and considered a series of questions related to aspects of the topic.University of Hohenheim, Stuttgart, Germany.The experts met and discussed the questions and arrived at a consensus.Total intake of glutamate from food in European countries is generally stable and ranged from 5 to 12 g/day (free: ca. 1 g, protein-bound: ca. 10 g, added as flavor: ca. 0.4 g). L-Glutamate (GLU) from all sources is mainly used as energy fuel in enterocytes. A maximum intake of 6.000 [c…

AdultMalemedicine.medical_specialtyAdolescentMonosodium glutamatePopulationMedicine (miscellaneous)Physiologychemistry.chemical_compoundBolus (medicine)Elderly personsPregnancyInternal medicineSodium GlutamatemedicineHumansPalatabilityChildeducationAgedAged 80 and overeducation.field_of_studyNutrition and DieteticsDose-Response Relationship DrugAppetite Regulationbusiness.industryInfant NewbornGlutamate receptorInfantMiddle AgedFood safetyFlavoring AgentsHuman nutritionEndocrinologychemistryBlood-Brain BarrierConsumer Product SafetyChild PreschoolPrenatal Exposure Delayed EffectsFemaleFood AdditivesbusinessEuropean Journal of Clinical Nutrition
researchProduct

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

2012

BACKGROUND: Some patients with severe asthma have recurrent asthma exacerbations associated with eosinophilic airway inflammation. Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. We aimed to establish efficacy, safety, and patient characteristics associated with the response to mepolizumab. METHODS: We undertook a multicentre, double-blind, placebo-controlled trial at 81 centres in 13 countries between Nov 9, 2009, and Dec 5, 2011. Eligible patients were aged 12-74 years, had a history of recurrent severe asthma exacerbations, and had signs of eosinophil…

AdultMalemedicine.medical_specialtyAdolescentPlacebo-controlled studyFevipiprantAntibodies Monoclonal HumanizedPlaceboLebrikizumabDrug Administration ScheduleLeukocyte CountYoung Adultchemistry.chemical_compoundDouble-Blind MethodReslizumabInternal medicineSecondary PreventionmedicineHumansAnti-Asthmatic AgentsPulmonary EosinophiliaChildGlucocorticoidsAgedAsthmaDose-Response Relationship Drugbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseBenralizumabAsthmaEosinophilsTreatment OutcomechemistryPhysical therapyDrug Therapy CombinationFemaleInterleukin-5businessMepolizumabmedicine.drugThe Lancet
researchProduct

Treatment of human brucellosis with rifampin plus minocycline

2003

In order to evaluate the efficacy and tolerability of a high intravenous dose of rifampin plus oral minocycline (administered daily for 3 weeks) for the treatment of acute brucellosis, we retrospectively reviewed the outcome of 239 consecutive patients (135 adults and 104 children) diagnosed and treated over a 17-year period in Italy. The combination used resulted in 100% response and a relapse rate lower than 2%. Fifty-two (30 adults and 22 children) (29.8%) complained of mild adverse effects including an increase in aspartate aminotransferase (>250 IU) observed in 12 cases and considered related to rifampin and in 11 cases a reversible hyperpigmentation of the tongue attributed to minocyc…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentMinocyclineRisk AssessmentDrug Administration SchedulePharmacotherapyRecurrenceInternal medicinemedicineHumansPharmacology (medical)ChildInfusions IntravenousAdverse effectAgedRetrospective StudiesAntibacterial agentAged 80 and overPharmacologyChemotherapyDose-Response Relationship Drugbusiness.industryRetrospective cohort studyMinocyclineMiddle AgedBrucellaSurgeryTreatment OutcomeInfectious DiseasesItalyOncologyTolerabilityChild PreschoolbrucellosisDrug Therapy CombinationFemaleRifampinbusinessRifampicinFollow-Up Studiesmedicine.drug
researchProduct

Subjective, behavioral, and physiological responses to the rubber hand illusion do not vary with age in the adult phase.

2018

[EN] The Rubber Hand Illusion (RHI) is a perceptual illusion that enables integration of artificial limbs into the body representation through combined multisensory integration. Most previous studies investigating the RHI have involved young healthy adults within a very narrow age range (typically 20-30 years old). The purpose of this paper was to determine the influence of age on the RHI. The RHI was performed on 93 healthy adults classified into three groups of age (20-35 years old, N = 41; 36-60 years old, N = 28; and 61-80 years old, N = 24), and its effects were measured with subjective (Embodiment of Rubber Hand Questionnaire), behavioral (proprioceptive drift), and physiological (cha…

AdultMalemedicine.medical_specialtyAgingmedia_common.quotation_subjectSkin temperatureIllusionExperimental and Cognitive PsychologyAudiologyRubber hand illusion050105 experimental psychologyDevelopmental psychology03 medical and health sciencesEmbodimentYoung Adult0302 clinical medicineArts and Humanities (miscellaneous)Age groupsTEORIA DE LA SEÑAL Y COMUNICACIONESDevelopmental and Educational PsychologymedicineMultisensory integrationHumans0501 psychology and cognitive sciencesmedia_commonAgedAged 80 and overProprioceptionPerceptual illusion05 social sciencesSkin temperatureMultisensory integrationINGENIERIA TELEMATICAGalvanic Skin ResponseMiddle AgedHandProprioceptionIllusionsArtificial limbsPhysiological responsesTouch PerceptionSkin conductanceVisual PerceptionFemalePsychologyBody-ownershipSkin Temperature030217 neurology & neurosurgeryConsciousness and cognition
researchProduct

Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dos…

2015

ABSTRACT Isavuconazole is a novel broad-spectrum triazole antifungal agent. This open-label dose escalation study assessed the safety and pharmacokinetics of intravenous isavuconazole prophylaxis in patients with acute myeloid leukemia who had undergone chemotherapy and had preexisting/expected neutropenia. Twenty-four patients were enrolled, and 20 patients completed the study. The patients in the low-dose cohort ( n = 11) received isavuconazole loading doses on day 1 (400/200/200 mg, 6 h apart) and day 2 (200/200 mg, 12 h apart), followed by once-daily maintenance dosing (200 mg) on days 3 to 28. The loading and maintenance doses were doubled in the high-dose cohort ( n = 12). The mean ± …

AdultMalemedicine.medical_specialtyAntifungal AgentsNeutropeniaPyridinesClinical TherapeuticsNeutropeniaCohort StudiesPharmacokineticsInternal medicineNitrilesHumansMedicinePharmacology (medical)DosingAdverse effectAgedImmunosuppression TherapyPharmacologyDose-Response Relationship Drugbusiness.industryMiddle AgedTriazolesmedicine.diseaseIsavuconazoniumSurgeryLeukemia Myeloid AcuteInfectious DiseasesMycosesTolerabilityCohortFemalePatient Safetybusinessmedicine.drugCohort studyAntimicrobial Agents and Chemotherapy
researchProduct

Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

2011

To define better the safety profile of micafungin, an analysis of micafungin clinical trial safety data was undertaken.Adverse event data were pooled worldwide from 17 clinical efficacy and safety studies. Adverse events were coded using the Medical Dictionary for Regulatory Activities version 5.0.In the pooled clinical trial data set, 3028 patients received at least one dose of micafungin. The mean age of patients was 41.4 years; with 296 (9.8%) children (16 years) and 387 (12.8%) elderly patients (≥ 65 years). Common underlying conditions were hematopoietic stem cell and other transplantations (26.1%), malignancies (20.8%) and HIV (32.9%). Mean exposure was 18 days for adults and 29 days …

AdultMalemedicine.medical_specialtyAntifungal AgentsTime FactorsAdolescentDatabases FactualNauseaMedDRAEchinocandinsLipopeptidesYoung AdultInternal medicinemedicineHumansPharmacology (medical)ChildAdverse effectAgedAged 80 and overClinical Trials as TopicDose-Response Relationship Drugbusiness.industryAge FactorsMicafunginInfantGeneral MedicineMiddle AgedHypokalemiaSurgeryClinical trialDiarrheaMycosesChild PreschoolMicafunginVomitingFemalemedicine.symptombusinessmedicine.drugExpert Opinion on Drug Safety
researchProduct